(Q47867006)

English

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice

scientific article published on 16 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

object named as

Jaap Goudsmit

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

Marie-Claude Dubois

7

object named as

Marie-Claude Dubois

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

D. Gray Heppner

14

object named as

D Gray Heppner

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

author name string

Joseph P Shott

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Shannon M McGrath

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Maria Grazia Pau

3

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Jerome H V Custers

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Olga Ophorst

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Marie-Ange Demoitié

6

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Jack Komisar

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Michelle Cobb

9

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Kent E Kester

10

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Patrice Dubois

11

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Joe Cohen

12

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

V Ann Stewart

15

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

language of work or name

0 references

publication date

16 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

26

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

23

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

2818-2823

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Efficient induction of protective anti-malaria immunity by recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Assay, purification and characterization of a recombinant malaria circumsporozoite fusion protein by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Localization of regions in CD46 that interact with adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

The global distribution of clinical episodes of Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.080

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.03.080

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/18455276

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47867006&oldid=2173587468"